REAL SCIENCE. REAL POSSIBILITIES.An established medicine for reducing deep abdominal fat in adults with HIV-associated lipodystrophy, tesamorelin is also studied in body-composition and liver-fat research.
Tesamorelin is unusual among popular peptide discussions because it has a licensed clinical use. The clearest benefits relate to visceral adipose tissue in adults with HIV-associated lipodystrophy.
These cards show what Tesamorelin is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
Reducing visceral fat — the deeper fat stored around the abdominal organs — is where tesamorelin has its clearest and strongest human evidence.
Randomized trials in adults with HIV-associated abdominal fat accumulation reported significant reductions in visceral adipose tissue.
Tesamorelin has also attracted interest for its potential to reduce fat stored in the liver in some people living with HIV.
A randomized multicentre trial reported a greater reduction in hepatic fat fraction than placebo over 12 months.
Tesamorelin encourages the body to release more of its own growth hormone, which in turn raises IGF-1 and helps explain its effects on body fat.
This endocrine mechanism is established, but higher IGF-1 is a biological effect rather than a stand-alone health benefit.
Because tesamorelin can target visceral fat, there is understandable interest in whether it can change body composition without simply producing general weight loss.
Clinical trials measured visceral and subcutaneous fat separately; use for general body recomposition remains outside the approved indication.
A stabilised signal designed to engage the pituitary GHRH receptor.
→Stimulates the body's own pulsatile growth-hormone release.
→A measurable pharmacological effect that also creates a monitoring need.
→Established in adults with HIV-associated excess abdominal fat.
The mechanism, dose and outcome are supported by human trials and an approved medicine. The limitation is scope: that evidence belongs to a defined HIV-lipodystrophy population, not every body-composition goal.
Tesamorelin stimulates pituitary growth-hormone release and raises IGF-1. Its strongest evidence is not generic fat loss: it is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, with additional human liver-fat research in HIV.
Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone rather than growth hormone itself.
It stimulates endogenous pulsatile GH release, which in turn increases circulating IGF-1.
Randomized trials established a reduction in visceral adipose tissue in adults with HIV and excess abdominal fat.
The approved result does not establish routine weight loss, bodybuilding or athletic-recovery efficacy.
412 adults with HIV and excess abdominal fat
Adults living with HIV with excess abdominal fat
Adults living with HIV and abdominal fat accumulation
61 adults living with HIV and hepatic steatosis
Multiple randomized human trials support effects on visceral fat in adults with HIV-associated lipodystrophy.
Clinical efficacy is established for a narrow approved indication, not general weight loss or bodybuilding.
Product labelling and trials provide meaningful safety data, including glucose, IGF-1, malignancy and injection-site considerations.
Preclinical and mechanistic work supports GHRH-receptor and GH-axis effects.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Tesamorelin has passed the human-evidence threshold for one use. The page separates that established result from adjacent questions that remain promising, exploratory or unsupported.
Randomized phase 3 evidence and a current US prescribing label.
Positive controlled human trials, but not the labelled indication.
No direct efficacy programme supports transferring the approved result.
Real interest begins with a proven visceral-fat result, then moves into liver fat, body composition and broader goals that need their own evidence.
Licensed use · human research · off-label boundariesCommunity interest often extends tesamorelin's visceral-fat evidence into general fat loss, muscle preservation and 'body recomposition'. The approved evidence is narrower than those broader claims.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
The licensed visceral-fat story drives most online interest.
Randomized trials support visceral-fat reduction in adults with HIV-associated lipodystrophy.
Mechanistic work supports GHRH-driven GH release and downstream lipolytic biology.
A real human benefit in a specific population, not proof of general fat-loss superiority.
Fatty-liver discussions have grown following a positive HIV-associated NAFLD trial.
A 12-month randomized trial reported lower hepatic fat fraction.
GH-axis effects offer metabolic rationale, but the clinical trial is more informative here.
Promising human evidence that remains population-specific.
Body-composition communities sometimes frame tesamorelin as a muscle-preserving or recovery peptide.
Existing trials were not designed to establish bodybuilding, athletic recovery or sarcopenia treatment claims.
GH/IGF-1 biology is relevant but does not prove a net functional benefit.
Mechanistically plausible, but broader performance claims overreach the evidence.
Interest often moves from the real visceral-fat result to hopes for overall weight loss or a leaner appearance.
The current FDA label states that EGRIFTA WR is not indicated for weight-loss management and describes a weight-neutral effect.
Endocrine and lipolysis mechanisms cannot establish a general obesity benefit without direct trials.
The strongest boundary on the page: selective visceral-fat evidence in HIV lipodystrophy is not a general weight-loss result.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toTesamorelin, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
The March 2025 prescribing information gives a formulation-specific once-daily dose. It does not describe routine dose escalation or a fixed cycle-and-break schedule.
Screen contraindications; evaluate glucose status
Subcutaneous abdomen; rotate injection sites
IGF-1, glucose, response and adverse effects
Reassess benefit when visceral fat is not reduced
Major clinical trials used 2 mg once daily with an earlier formulation. That historical protocol should not overwrite the current 1.28 mg EGRIFTA WR label.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
Tesamorelin has a licensed, formulation-specific dose for its approved indication. EGRIFTA WR and EGRIFTA SV are not interchangeable, and use outside the indication is a different evidence question.
Adults with HIV and lipodystrophy who have excess abdominal fat
Published study structure, shown as data — not a personal dosing schedule.
This is the current EGRIFTA WR dose only. The label states that WR and SV formulations differ and are not substitutable; treatment response, IGF-1 and glucose require clinical review.
412 adults with HIV and excess abdominal fat
Published study structure, shown as data — not a personal dosing schedule.
This historical trial used an earlier formulation and supported development in a defined HIV-associated population. It is not the current EGRIFTA WR dose or a general weight-loss schedule.
Community discussions often borrow either the older 2 mg trial amount or a marketed formulation's daily dose for goals that were never studied. Those numbers are formulation- and indication-specific.
Short cycles and longer continuous use are both discussed online, but no community cycle has been validated for general fat loss, bodybuilding or recovery.
There is no evidence-based maintenance, cycling or break schedule for general body composition. Licensed treatment uses clinician-led monitoring and response review.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Tesamorelin + Resistance training
Tesamorelin + Dietary and cardiometabolic care
Tesamorelin + GLP-1 receptor agonist
Its strongest evidence is an approved clinical use—not general appetite suppression, total weight loss or athletic enhancement.
That may make clinical sense in an individual care plan, but it does not create combination evidence or expand tesamorelin's licence.
Discussed around visceral-fat reduction, function and lean-tissue goals.
Exercise benefits are established; no controlled trial has shown that tesamorelin adds athletic or muscle-building benefit.A structured care plan can address broader metabolic risk while tesamorelin's licensed role remains focused on excess abdominal fat in HIV lipodystrophy.
Clinically coherent in the approved population, but outcomes depend on the complete care plan rather than the peptide alone.Explored where visceral adiposity and broader obesity or glucose goals overlap.
Specialist-only discussion: combination-specific efficacy and safety have not been established, and glucose monitoring matters.Visceral fat, total weight, liver fat and muscle performance are different outcomes.
Benefits of exercise or a GLP-1 medicine do not prove that adding tesamorelin improves them.
IGF-1, glucose, fluid retention and treatment interactions make clinician oversight especially important.
Tesamorelin has controlled human exposure data, common adverse reactions, contraindications and explicit monitoring requirements.
The label calls for glucose evaluation before and during treatment, IGF-1 monitoring and reassessment where benefit is not clear.
Hypersensitivity is also a contraindication. A prior malignancy requires a careful benefit-risk assessment under the label.
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Injection-site reactions, arthralgia, myalgia, limb pain and peripheral oedema appear in the label.
Baseline and periodic glucose assessment matters, especially when broader metabolic therapies are also being considered.
The current label explicitly notes this limitation and recommends weighing continuation when visceral fat is not reduced.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
Approved to reduce excess abdominal fat in HIV-infected adult patients with lipodystrophy; not indicated for general weight-loss management.
FDA Drugs@FDA · EGRIFTA ↗The US approval should not be assumed to create a UK marketing authorisation or a general weight-management indication.
MHRA products database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.
